<DOC>
	<DOCNO>NCT00317109</DOCNO>
	<brief_summary>The purpose study assess safety reactogenicity booster dose diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine ( DTPw-HBV/Hib ) 15-18 assess immunogenicity , safety , reactogenicity dose Mencevax™ Group A , C W135 polysaccharide meningococcal vaccine ( ACW ) 24 30 primed subject . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Study Asses DTPw-HBV/Hib 15-18 Months ( ) Mencevax™ ACW 24 30 Primed Subjects</brief_title>
	<detailed_description>This open study two parallel group base vaccination receive primary study : AC prim Group : prim Tritanrix™-HepB/Hib-MenAC vaccine AC unprimed Group ( control ) : prim Tritanrix™-HepB/Hiberix™ vaccine . All subject receive booster dose Tritanrix™-HepB/Hiberix™ vaccine 15 18 month age GSK Biological 's OPV vaccine give concomitantly dose Mencevax™ ACW vaccine 24 30 month age . Blood sample do prior ( pre ) one month ( post ) Mencevax™ ACW vaccine administration immunogenicity analysis . The study last minimum 7 maximum 16 month per subject . Mencevax™ ACWY change Mencevax™ ACW throughout post correct inconsistency earlier version protocol post reflect actual situation .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 15 18 month age time vaccination . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having participate primary vaccination study ( CPMS N° 759346/007 ) . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede vaccination , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/ administration vaccine foreseen study protocol within 30 day vaccination . Booster vaccination diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b ( Hib ) and/or meningococcal serogroups A , C W disease , date study conclusion visit primary vaccination study ( CPMS N° 759346/007 ) . History diphtheria , tetanus , pertussis , hepatitis B , Hib and/or meningococcal serogroup A , C W disease . Known exposure diphtheria , tetanus , pertussis , hepatitis B , Hib and/or meningococcal serogroup A , C W disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine administer study . Major congenital defect serious chronic illness . History neurologic disorder seizure include febrile seizure infancy . Acute disease time enrolment . Axillary temperature ≥ 37.5°C time vaccination . Administration immunoglobulins and/or blood product within three month precede vaccination plan administration study period . Anaphylactic reaction follow administration vaccine primary vaccination study . Known hypersensitivity component vaccine , subject show sign hypersensitivity previous administration diphtheria , tetanus , pertussis , hepatitis B , Hib meningococcal vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>meningococcal serogroups A C disease</keyword>
	<keyword>tetanus</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>pertussis</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>meningococcal vaccine</keyword>
	<keyword>Prophylaxis diphtheria</keyword>
</DOC>